How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Noninvasive Delivery Vaccine Market
- By Delivery Method: Oral Delivery, Nasal Spray, Transdermal Patch, Inhalation, Microneedle Patch
- By Vaccine Type: Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, mRNA Vaccines, Viral Vector Vaccines
- By Target Disease: Influenza, COVID-19, Measles, Tuberculosis, Human Papillomavirus (HPV)
- By End User: Hospitals, Clinics, Pharmacies, Home Care Settings, Public Health Centers
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Oral Delivery leads By Delivery Method at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Noninvasive Delivery Vaccine Market report
A complete, evidence-based study - 11 chapters and 119 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Delivery Method 5
Vaccine Type 5
Target Disease 5
End User 5
Companies profiled
GlaxoSmithKline plc
Sanofi Pasteur
Pfizer Inc.
Moderna Inc.
Johnson & Johnson
AstraZeneca plc
Becton
Dickinson and Company (BD)
Bharat Biotech International Ltd.
Medicago Inc.
Vaxart Inc.
Altimmune Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →GlaxoSmithKline plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Sanofi Pasteur
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Moderna Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Johnson & Johnson
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →AstraZeneca plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Dickinson and Company (BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Bharat Biotech International Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Medicago Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Vaxart Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Altimmune Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →ZyCoV-D (Zydus Cadila)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Inovio Pharmaceuticals Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →CureVac N.V.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Becton Dickinson
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,095M by 2033 · 4.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Oral Delivery37.5
- Nasal Spray17.7
- Transdermal Patch17.6
- Inhalation16.9
- Microneedle Patch10.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$990.4M → $1,325M · 3.7%
Europe$690.3M → $981.7M · 4.5%
Asia Pacific$630.2M → $961.4M · 5.4%
Latin America$390.1M → $505.1M · 3.3%
Middle East and Africa$300.1M → $462.1M · 5.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.912026
3.932027
3.932028
3.952029
3.972030
3.982031
3.982032
4.002033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- GlaxoSmithKline plc14.9
- Sanofi Pasteur14.9
- Pfizer Inc.14.9
- Moderna Inc.10.8
- Johnson & Johnson7.9
- AstraZeneca plc8.6
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Delivery Method31.3%
Vaccine Type35.3%
Target Disease18.2%
End User15.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.3
- Europe23.2
- Asia Pacific22.7
- Latin America11.9
- Middle East and Africa10.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| GlaxoSmithKline plc | 85 | 89 | 89 | 83 | 92 | 96 | 89 |
| Sanofi Pasteur | 80 | 92 | 87 | 88 | 72 | 90 | 85 |
| Pfizer Inc. | 76 | 68 | 72 | 69 | 77 | 84 | 74 |
| Moderna Inc. | 76 | 57 | 82 | 60 | 57 | 64 | 66 |
| Johnson & Johnson | 72 | 60 | 71 | 76 | 58 | 71 | 68 |
| AstraZeneca plc | 48 | 46 | 49 | 62 | 49 | 53 | 51 |
| Becton | 61 | 46 | 52 | 64 | 44 | 63 | 55 |
| Dickinson and Company (BD) | 40 | 57 | 56 | 58 | 52 | 38 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- GlaxoSmithKline plc
- Sanofi Pasteur
- Pfizer Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| GlaxoSmithKline plc | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Sanofi Pasteur | ✓ | ◐ | ✓ | ✓ | ◐ | ✓ |
| Pfizer Inc. | ◐ | ✓ | ◐ | ✓ | ◐ | ✓ |
| Moderna Inc. | ◐ | − | ✓ | − | ◐ | ✓ |
| Johnson & Johnson | ◐ | ◐ | − | ◐ | − | ◐ |
| AstraZeneca plc | − | ◐ | − | − | − | ◐ |
| Becton | ◐ | − | − | ◐ | − | ◐ |
| Dickinson and Company (BD) | − | ◐ | ◐ | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1GlaxoSmithKline plc89
2Sanofi Pasteur85
3Pfizer Inc.74
4Johnson & Johnson68
5Moderna Inc.66
6Becton55
7AstraZeneca plc51
8Dickinson and Company (BD)50
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
GlaxoSmithKline plcSanofi Pasteur
Challenger2
Strong scale, closing on the leaders.
Pfizer Inc.Johnson & Johnson
Contender1
Focused players with pockets of strength.
Moderna Inc.
Niche3
Specialists in a single segment or region.
AstraZeneca plcBectonDickinson and Company (BD)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Delivery Method in North America, then scale across Noninvasive Delivery Vaccine Market — a $506M beachhead inside a $9.19B market.
Beachhead (SOM)$506Mobtainable near-term
Serviceable (SAM)$3.22Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Oral Delivery
Best fit — highest urgency & budget in Delivery Method.
Economic buyer79 fit
Nasal Spray
Strong fit — clear ROI and a fast path to value.
End user67 fit
Transdermal Patch
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Delivery Method in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Vaccine Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Target Disease
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel27%
Digital / self-serve22%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Delivery Method leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Noninvasive Delivery Vaccine Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified20%
Evaluation12%
Closed-won7%
$18.8KCAC
$112KLTV
5.9:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Noninvasive Delivery Vaccine Market is a resilient opportunity — $4.84B by 2033, compounding at 4.3%.
TAM · 2025$3.47Btoday
TAM · 2033$4.84Bforecast
CAGR4.3%2027–2033
Cumulative$37.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.84BTotal addressable market
SAM$1.67BServiceable available market
SOM$296MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.3% CAGR
Demand compounds through 2033, outpacing GDP across Delivery Method.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Delivery Method moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.84BLarge & growingTAM by 2033 at 4.3% CAGR
$1.67BServiceable nowreachable with today’s model
$296MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.78BBear2.8% CAGR
$4.84BBase4.3% CAGR
$6.20BBull5.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Vaccine Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Noninvasive Delivery Vaccine Market — a $8.68B market by 2033. Plan: grow share from 8.8% to 17.5%.
Market size · 2033$8.68Btotal addressable
Market CAGR7.0%2027–2033
Target share17.5%from 8.8% today
Revenue ambition$1.52Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.8% | 17.5% | On track |
| Revenue | $757M | $1.52B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 36.7% | 41.8% | At risk |
| Customer retention | 89.6% | 93.8% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Delivery Method
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Vaccine Type capability
A defensible second engine — invest in Vaccine Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Delivery Method share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Vaccine Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $207M capacity & capability investment
- Greenlight bolt-on M&A in Vaccine Type
- Authorise North America expansion plan
- Fund R&D program for Delivery Method leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskAhead
- Regulatory / policy changeAhead
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Noninvasive Delivery Vaccine Market conversation — a $9.15B market you can size, segment and defend in minutes.
Market size · 2033$9.15Btotal opportunity
Growth8.2%CAGR to 2033
Addressable buyers1,590+accounts in scope
Typical ROI5.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Delivery Method
Goal Grow share in Delivery Method
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.6×return on cost, year one
< 4 mopayback period
$41K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
GlaxoSmithKline plcSanofi PasteurPfizer Inc.Moderna Inc.Johnson & JohnsonAstraZeneca plcBectonDickinson and Company (BD)+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Noninvasive Delivery Vaccine Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Noninvasive Delivery Vaccine Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Non-Invasive Cryolipolysis Machine Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportNon-invasive CPAP Ventilator Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportNon-Invasive Cosmetic Treatments Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportNon-invasive Coronary Imaging Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportNoninvasive Continuous Hemodynamic Monitor Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportNon-invasive Continuous Glucose Monitor Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportNon Invasive Colon Cancer Screening Market
Market size, share, segmentation and regional forecast.
$953M market · 2025 base year
View reportNon-invasive Cerebral Oxygen Monitor Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportNon-invasive Cerebral Edema Monitor Market
Market size, share, segmentation and regional forecast.
$459M market · 2025 base year
View reportNon-Invasive Cardiac Output Monitoring Device Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportNoninvasive Cancer Diagnostics Technology Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportNoninvasive Cancer Diagnostics and Technology Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.